drugset / Trial / NCT04090684

Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04090684

Phase 1 Completed 10 enrolled NeuroSense Therapeutics Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).

Timeline

Start
2019-12-09
Primary completion
2021-09-27
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified
Subject Ciprofloxacin Small molecule